Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Genenta Science SpA Sponsored ADR ( (GNTA) ) is now available.
Genenta Science S.p.A. has announced an amendment to its ATM Sales Agreement, initially signed in April 2024. The amendment involves replacing Capital One Securities, Inc. with Rodman & Renshaw LLC as an agent for the sale of American Depositary Shares, which signifies a strategic shift in their financial operations. This change could impact the company’s market dynamics and stakeholder relations, potentially enhancing their financial capabilities and market reach.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. operates in the biotechnology industry, focusing on developing gene therapies for cancer treatment. The company is known for its innovative approaches in oncology, targeting various cancer types through advanced therapeutic techniques.
YTD Price Performance: 8.28%
Average Trading Volume: 13,755
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $98.03M
Find detailed analytics on GNTA stock on TipRanks’ Stock Analysis page.
